TABLE 3.

Percent Reduction of Dose of Inhaled Beclomethasone Dipropionate, Relative to Baseline, During the Steroid-Reduction and Open-Label Phases

WeekOmalizumabPlacebo
nMeanSDnMeanSDP Value
181516.212.6718.422.8.76
201732.521.7937.527.4.77
221046.726.9847.128.3.55
241555.730.0964.527.0.56
261168.729.4861.735.4.61
28*1150.764.8959.136.3.48
361357.238.5776.234.8.82
521367.465.7794.1615.4.75
  • * End of steroid-reduction phase. At this time point, all placebo-treated patients were switched to omalizumab therapy.